Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stem cells vs. platelets: which boosts knee repair best?

NCT ID NCT04775004

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two biologic techniques used during meniscal tear surgery: a bone marrow venting procedure (BMVP) that releases stem cells, and a platelet-rich plasma (PRP) injection from the patient's own blood. About 146 participants aged 16 and older with specific meniscal tears will be randomly assigned to one method. The goal is to see which approach leads to better knee function and fewer re-tears over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bone marrow venting procedure (BMVP) and Platelet Rich Plasma (PRP)
What this could lead to
If successful, this could show which biologic augmentation method better improves meniscal repair success and reduces re-tear rates.
What could go wrong
This is a relatively small, early-stage comparative trial without a placebo group, so results may not be definitive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age 16 or older 2. Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear 3. Complex tears may be included at the discretion of the site investigator if patient has one of tear patterns listed in inclusion criteria 2 as the most predominant finding 4. No other concomitant procedure unless one of the following: * Chondroplasty * Synovectomy * Loose body removal * "Contralateral" menisectomy (i.e. medial meniscus repair with a lateral menisectomy or lateral meniscus repair with a medial menisectomy) would be permitted for inclusion * Any other procedure that does not include drilling, requires prior approval of the study sponsor for each procedure Exclusion Criteria 1. Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation, micro-fracture repair, or others) 2. Patients with meniscus root tears 3. Patients undergoing repair for horizontal cleavage tears 4. Kellgren-Lawrence scale 3\> 5. Patients undergoing lateral release 6. Ipsilateral chondral lesion with Outerbridge classification of 3-4 7. Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week before surgery or expected use within six weeks after surgery 8. Cortisone use within the six weeks prior to surgery 9. Utilizing worker's compensation at the time of screening 10. Any previous ligament surgery on the index limb. Any previous meniscal surgery on the index meniscus. 11. Concomitant ligamentous insufficiency 12. Inflammatory rheumatic disease or other rheumatic disease 13. Immune compromised patients (hepatitis, HIV, etc.) 14. Any nicotine based products within the three months prior to surgery (including cigarettes, cigars, vaping, nicotaine patch, etc) 15. History of distal femur, proximal tibia, or patellar fracture that was treated operatively 16. Non English-speaking patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meniscal tear are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Chicago Medicine

    Chicago, Illinois, 60637, United States

  • University of Florida

    Gainesville, Florida, 32611, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.